(Q40833573)

24 September 2017

1 reference

title

Cytokine combinations in immunotherapy for solid tumors: a review (English)

1 reference

24 September 2017

1 reference

K M Heaton

1

1 reference

24 September 2017

E A Grimm

series ordinal

2

1 reference

24 September 2017

1 September 1993

1 reference

Cancer Immunology, Immunotherapy

24 September 2017

1 reference

24 September 2017

37

1 reference

24 September 2017

4

1 reference

24 September 2017

213-219

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01518513

24 September 2017

0 references

cites work

Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01518513

Phase I Trial of Interleukin-2 plus Gamma-Interferon

21 January 2018

1 reference

12 December 2020

Antitumor activity of recombinant interleukin 6 in mice

1 reference

12 December 2020

IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4

1 reference

12 December 2020

Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma

1 reference

12 December 2020

Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases

1 reference

12 December 2020

Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study

1 reference

12 December 2020

Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2

1 reference

12 December 2020

Phase I Trial of Continuous Infusion Interleukin-2 and Doxorubicin in Patients with Refractory Malignancies

1 reference

12 December 2020

Interleukin 1 as an adjuvant for active specific immunotherapy in a murine tumor model

1 reference

12 December 2020

Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro

1 reference

12 December 2020

A prospective randomized trial of alpha 2B-interferon/gamma-interferon or the combination in advanced metastatic renal cell carcinoma

1 reference

12 December 2020

Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases

1 reference

12 December 2020

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

12 December 2020

Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C

1 reference

12 December 2020

Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma.

1 reference

12 December 2020

Phase I Study of Low-Dose Cyclophosphamide and Recombinant Interleukin-2 for the Treatment of Advanced Cancer

1 reference

12 December 2020

Sequential dacarbazine/cisplatin and interleukin-2 in metastatic melanoma: immunological effects of therapy

1 reference

12 December 2020

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

1 reference

12 December 2020

Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects

1 reference

12 December 2020

Regulation of human cytolytic lymphocyte responses by interleukin-12

1 reference

12 December 2020

Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha

1 reference

12 December 2020

Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma

1 reference

12 December 2020

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

12 December 2020

Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience

1 reference

12 December 2020

Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma

1 reference

12 December 2020

Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity

1 reference

12 December 2020

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

1 reference

12 December 2020

Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model

1 reference

12 December 2020

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

1 reference

12 December 2020

Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancer.

1 reference

12 December 2020

A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.

1 reference

12 December 2020

Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer

1 reference

12 December 2020

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1 reference

12 December 2020

The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes

1 reference

12 December 2020

Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon

1 reference

12 December 2020

A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer

1 reference

12 December 2020

Immunotherapy with IL2 by Constant Infusion and Weekly Doxorubicin

1 reference

12 December 2020

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

12 December 2020

Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.

1 reference

12 December 2020

A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma

1 reference

12 December 2020

Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study

1 reference

12 December 2020

A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma

1 reference

12 December 2020

Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study

1 reference

12 December 2020

Cytokines and cytotoxic agents in renal cell carcinoma: a review

1 reference

12 December 2020

Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer.

1 reference

12 December 2020

On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.

1 reference

12 December 2020

A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo

1 reference

12 December 2020

A phase I study of recombinant interleukin 2 plus recombinant beta-interferon

1 reference

12 December 2020

Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer

1 reference

12 December 2020

In vivo effects of combination treatment with recombinant interferon-gamma and -alpha in metastatic melanoma.

1 reference

12 December 2020

Interleukin-2: inception, impact, and implications

1 reference

12 December 2020

Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.

1 reference

12 December 2020

Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer

1 reference

12 December 2020

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1 reference

12 December 2020

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study

1 reference

12 December 2020

Phase I Evaluation of Recombinant Tumor Necrosis Factor Given in Combination With Recombinant Interferon-Gamma

1 reference

12 December 2020

Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor

1 reference

12 December 2020

A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma

1 reference

12 December 2020

Interactions between cytokines and cytotoxic drugs: putative molecular mechanisms in experimental hematology and oncology

1 reference

12 December 2020

Combined treatment of metastatic melanoma with interferons and cytotoxic drugs

1 reference

12 December 2020

Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01518513

1 reference

Dimensions Publication ID

24 September 2017

1008959376

0 references

Fatcat ID

release_vrsdkjgp25bxtk7zxfwt7gap5e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vrsdkjgp25bxtk7zxfwt7gap5e

24 November 2022

mapped directly with Wikidata item

1 reference